1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow BCR-ABL1 Fusion Protein Expression: new trials by email Literature Review of BCR-ABL1 Fusion Protein Expression trials Research Report on BCR-ABL1 Fusion Protein Expression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL Flumatinib - Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression | Phase 3 | Unknown | Zhongda Hospital | 28 | 2020-03-01 | 2022-03-24 |
Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
flumatinib (1)
Zhongda Hospital (1)
China (1)